Asia Deal Watch: I-Mab Partners With Sinopharm As It Readies First Regulatory Filing

I-Mab sets commercial plans with Sinopharm for felzartamab in multiple myeloma. Legochem and Antengene team up on antibody-drug conjugates, Luoxin licenses respiratory drug from Marinomed.